Foxo Technologies Inc
FOXO0.092USD
0.000
Handelsschluss 11/04, 16:00（ET）Kurse um 15 Minuten verzögert
31.56KMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Foxo Technologies Inc Unternehmen
FOXO Technologies Inc. is engaged in commercializing epigenetic biomarker technology to support groundbreaking scientific research and next-generation business initiatives. The Company owns and operates three subsidiaries: Foxo Labs, Inc., Myrtle Recovery Centers, Inc., and Rennova Community Health, Inc. It applies automated machine learning and artificial intelligence (AI) technologies to discover epigenetic biomarkers of human health, wellness and aging. Its segments include Healthcare and Labs and Life. The Healthcare segment offers behavioral health services, including substance abuse treatment. Services are provided on either an inpatient, residential basis or an outpatient basis. It offers alcohol and drug residential detoxification and residential rehabilitation treatment services for up to 30 patients. The Labs and Life segment is commercializing proprietary epigenetic biomarker technology to be used for underwriting risk classification in the global life insurance industry.
Foxo Technologies Inc Informationen
BörsenkürzelFOXO
Name des UnternehmensFoxo Technologies Inc
IPO-datumDec 11, 2020
CEOMr. Seamus Lagan
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
GeschäftsjahresendeDec 11
Addresse477 South Rosemary Avenue
StadtWEST PALM BEACH
BörseUS 'Other OTC' and Grey Market
LandUnited States of America
Postleitzahl33401
Telefon16128000059
Websitehttp://delwinds.com/
BörsenkürzelFOXO
IPO-datumDec 11, 2020
CEOMr. Seamus Lagan
Führungskräfte von Foxo Technologies Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Bret Barnes
Mr. Bret Barnes
Director
Director
168.00
+0.60%
Mr. Mark K. White
Mr. Mark K. White
Chief Executive Officer and sole director of FOXO Labs Inc. and Director
Chief Executive Officer and sole director of FOXO Labs Inc. and Director
--
--
Mr. Seamus Lagan
Mr. Seamus Lagan
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Trevor Langley
Mr. Trevor Langley
Chairman of the Board
Chairman of the Board
--
--
Mr. Francis Colt Dewolf, III
Mr. Francis Colt Dewolf, III
Independent Director
Independent Director
--
--
Sylwia Hauman
Sylwia Hauman
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Bret Barnes
Mr. Bret Barnes
Director
Director
168.00
+0.60%
Mr. Mark K. White
Mr. Mark K. White
Chief Executive Officer and sole director of FOXO Labs Inc. and Director
Chief Executive Officer and sole director of FOXO Labs Inc. and Director
--
--
Mr. Seamus Lagan
Mr. Seamus Lagan
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Trevor Langley
Mr. Trevor Langley
Chairman of the Board
Chairman of the Board
--
--
Mr. Francis Colt Dewolf, III
Mr. Francis Colt Dewolf, III
Independent Director
Independent Director
--
--
Sylwia Hauman
Sylwia Hauman
Chief Financial Officer
Chief Financial Officer
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Wed, Oct 22
Aktualisiert: Wed, Oct 22
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Rennova Health, Inc.
0.07%
UBS Financial Services, Inc.
0.06%
Jane Street Capital, L.L.C.
0.02%
Two Sigma Investments, LP
0.02%
Kr8 ai Inc
0.02%
Andere
99.81%
Aktionäre
Aktionäre
Anteil
Rennova Health, Inc.
0.07%
UBS Financial Services, Inc.
0.06%
Jane Street Capital, L.L.C.
0.02%
Two Sigma Investments, LP
0.02%
Kr8 ai Inc
0.02%
Andere
99.81%
Aktionärstypen
Aktionäre
Anteil
Corporation
0.08%
Investment Advisor
0.08%
Research Firm
0.04%
Hedge Fund
0.02%
Andere
99.78%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
34
113.13K
0.15%
+74.26K
2025Q2
43
122.62K
2.30%
-40.72K
2025Q1
44
283.42K
16.93%
-74.76K
2024Q4
45
2.97M
12.59%
-305.11K
2024Q3
42
2.93M
22.70%
-1.57M
2024Q2
66
3.17M
26.93%
-1.03M
2024Q1
108
4.13M
45.76%
-1.73M
2023Q4
115
3.33M
41.62%
-1.13M
2023Q3
119
2.33M
33.97%
-1.67M
2023Q2
124
2.96M
79.90%
-804.39K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Rennova Health, Inc.
51.44K
0.07%
+2.00
+0.00%
Sep 10, 2025
UBS Financial Services, Inc.
44.67K
0.06%
+37.12K
+491.99%
Jun 30, 2025
Jane Street Capital, L.L.C.
17.70K
0.02%
+17.70K
--
Jun 30, 2025
Two Sigma Investments, LP
16.26K
0.02%
+16.26K
--
Jun 30, 2025
Kr8 ai Inc
11.91K
0.02%
+1.00
+0.01%
Sep 10, 2025
SBI Securities Co., Ltd.
9.66K
0.01%
+7.10K
+277.06%
Jun 30, 2025
Cantor Fitzgerald, L.P
9.57K
0.01%
+8.62K
+900.21%
Jun 30, 2025
HRT Financial LP
6.83K
0.01%
+6.83K
--
Jun 30, 2025
Geode Capital Management, L.L.C.
6.42K
0.01%
-819.00
-11.32%
Jun 30, 2025
Corbin Capital Partners, L.P.
1.38K
0%
--
--
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Nov 15, 2024
Merger
0→0
Oct 30, 2023
Merger
10→1
Oct 30, 2023
Merger
10→1
Oct 30, 2023
Merger
10→1
Oct 30, 2023
Merger
10→1
Datum
Art
Verhältnis
Nov 15, 2024
Merger
0→0
Oct 30, 2023
Merger
10→1
Oct 30, 2023
Merger
10→1
Oct 30, 2023
Merger
10→1
Oct 30, 2023
Merger
10→1
